Thus, to evaluate the potential therapeutic implications of COX-2 upregulation by dying cancer cells for tumor immunity, we determined the impact of pharmacologically inhibiting COX-2 alongside ICB and CTX. The gene discussed is PTGS2; the disease is cancer.